This company has been acquired
Verona Pharma (VRNA) Stock Overview
A biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRNA from our risk checks.
VRNA Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Verona Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$106.91 |
| 52 Week High | US$106.93 |
| 52 Week Low | US$31.09 |
| Beta | 0.052 |
| 1 Month Change | 0.56% |
| 3 Month Change | 23.08% |
| 1 Year Change | 233.57% |
| 3 Year Change | 971.24% |
| 5 Year Change | 1,795.57% |
| Change since IPO | 691.93% |
Recent News & Updates
Verona Pharma: An Impressive Initial Launch
Jun 18
Ohtuvayre Launch And EU Approval Will Unlock Future Markets
Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential.Recent updates
Verona Pharma: An Impressive Initial Launch
Jun 18Ohtuvayre Launch And EU Approval Will Unlock Future Markets
Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential.This Just In: Analysts Are Boosting Their Verona Pharma plc (NASDAQ:VRNA) Outlook for This Year
May 01
Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Apr 12Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Mar 13New Forecasts: Here's What Analysts Think The Future Holds For Verona Pharma plc (NASDAQ:VRNA)
Mar 08Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results
Mar 02Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Jan 08Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Jan 07Verona Pharma: In COPD, There's A Corner With Their Name On It
Nov 27Verona Pharma: A Post FDA Approval Analysis
Sep 10Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Shareholder Returns
| VRNA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.3% | -1.6% | -1.2% |
| 1Y | 233.6% | -7.0% | 15.1% |
Return vs Industry: VRNA exceeded the US Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: VRNA exceeded the US Market which returned 18.4% over the past year.
Price Volatility
| VRNA volatility | |
|---|---|
| VRNA Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VRNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VRNA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 209 | Dave Zaccardelli | www.veronapharma.com |
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma plc Fundamentals Summary
| VRNA fundamental statistics | |
|---|---|
| Market cap | US$9.20b |
| Earnings (TTM) | -US$81.19m |
| Revenue (TTM) | US$221.67m |
Is VRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRNA income statement (TTM) | |
|---|---|
| Revenue | US$221.67m |
| Cost of Revenue | US$10.75m |
| Gross Profit | US$210.93m |
| Other Expenses | US$292.12m |
| Earnings | -US$81.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 95.15% |
| Net Profit Margin | -36.62% |
| Debt/Equity Ratio | 87.1% |
How did VRNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 20:36 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verona Pharma plc is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Thomas Shrader | BTIG |
| Olivia Brayer | Cantor Fitzgerald & Co. |